Related Experiment Video

Updated: Oct 10, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K

Hitting the Right Spot: Advances in the Treatment of NSCLC With Uncommon EGFR Mutations

Joshua K Sabari1, John V Heymach2, Beth Sandy3

  • 1NYU Perlmutter Cancer Center, New York, New York.

Journal of the National Comprehensive Cancer Network : JNCCN
|December 7, 2021
PubMed

Insights

Understanding uncommon epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) is crucial for selecting targeted therapies. This review covers current and emerging treatments for these specific EGFR mutations in NSCLC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Uncommon epidermal growth factor receptor (EGFR) mutations are increasingly recognized in non-small cell lung cancer (NSCLC).
  • These mutations impact targeted therapy selection and resistance mechanisms.
  • Genomic profiling is now standard for identifying these mutations in NSCLC.

Purpose of the Study:

  • To review the efficacy and safety of targeted therapies for uncommon EGFR mutations in NSCLC.
  • To provide insights for developing personalized treatment strategies for NSCLC patients with uncommon EGFR mutations.

Main Methods:

  • Literature review of current and emerging targeted therapies.
  • Analysis of clinical trial data and real-world evidence for uncommon EGFR mutations in NSCLC.

Main Results:

  • Discussion of approved and investigational therapies targeting specific uncommon EGFR mutations.
  • Evaluation of treatment outcomes, including response rates and progression-free survival.
  • Assessment of safety profiles and management of treatment-related toxicities.

Conclusions:

  • Targeted therapies are vital for managing NSCLC with uncommon EGFR mutations.
  • Personalized treatment plans based on specific mutation profiles are essential for optimal patient outcomes.
  • Ongoing research is expanding therapeutic options for these challenging mutations.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.1K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.1K